SeekingAlpha · Aug 20, 2026
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)
Buy XBI now: SPDR S&P Biotech ETF up 34% since March on M&A and trial catalysts.
XB
AMEX · XBI
SPDR S&P Biotech ETF
Financial Services · Asset Management
$162.38
Down-$5.85 (-3.48%)
Updated Aug 29, 2026, 10:29 AM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.38B
- P/E ratio
- —
- Dividend yield
- 0.03%
- 52-week range
- $118.19 – $169.89
- Volume
- 9.79M
- Avg. volume
- 10.76M
Price performance
XBI price history
1M range · 21 trading sessions · Daily adjusted prices
XBI closed at $162.38 after 21 trading sessions, up 10.46% for the selected period.
- Last close
- $162.38
- Period change
- +10.46%
- Period low
- $147.01
- Period high
- $169.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $166.72 | $167.12 | $162.16 | $162.38 | 9.79M |
| Aug 27, 2026 | $167.76 | $169.27 | $166.88 | $168.23 | 4.51M |
| Aug 26, 2026 | $168.08 | $169.045 | $166.50 | $168.39 | 8.95M |
| Aug 25, 2026 | $166.18 | $169.89 | $165.79 | $169.10 | 9.9M |
| Aug 24, 2026 | $164.99 | $165.55 | $161.49 | $164.17 | 8.53M |
| Aug 21, 2026 | $164.60 | $167.9112 | $163.74 | $165.73 | 10.02M |
| Aug 20, 2026 | $166.66 | $167.53 | $162.53 | $163.38 | 15.03M |
| Aug 19, 2026 | $165.70 | $169.68 | $164.50 | $169.55 | 14.09M |
| Aug 18, 2026 | $158.34 | $160.60 | $157.88 | $160.11 | 6.52M |
| Aug 17, 2026 | $156.83 | $159.86 | $155.86 | $159.53 | 6.36M |
| Aug 14, 2026 | $156.54 | $157.77 | $154.1506 | $157.41 | 6.32M |
| Aug 13, 2026 | $160.25 | $160.67 | $156.55 | $156.86 | 7.54M |
| Aug 12, 2026 | $158.14 | $160.09 | $157.19 | $159.39 | 6.05M |
| Aug 11, 2026 | $158.50 | $159.18 | $156.79 | $158.07 | 6.2M |
| Aug 10, 2026 | $155.98 | $158.55 | $155.00 | $158.03 | 7.45M |
| Aug 7, 2026 | $156.87 | $157.85 | $154.96 | $157.37 | 8.4M |
| Aug 6, 2026 | $153.95 | $156.89 | $153.14 | $154.50 | 8.78M |
| Aug 5, 2026 | $153.13 | $155.12 | $151.49 | $153.01 | 8.97M |
| Aug 4, 2026 | $148.77 | $152.21 | $147.94 | $151.88 | 7.84M |
| Aug 3, 2026 | $146.98 | $148.145 | $143.775 | $147.31 | 6.72M |
| Jul 31, 2026 | $151.20 | $151.77 | $146.00 | $147.01 | 8.04M |
Latest XBI news
The latest Smart Investors Daily articles mentioning XBI.
Stock researchCompany · Overview
XBI research
Overview
Company profile and research snapshot.
Company profile
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
‘Never Happened in History,’ Ex-Bridgewater Exec Warns AI Market Is Priced to Perfection
Former Bridgewater exec Bob Elliott warns the AI stock rally is an "expectations mania" built on unrealistic growth assumptions.
Yahoo · Aug 8, 2026
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.
Yahoo · Aug 3, 2026
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
